TY - JOUR
T1 - 13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia
AU - Dal Bo, Michele
AU - Rossi, Francesca Maria
AU - Rossi, Davide
AU - Deambrogi, Clara
AU - Bertoni, Francesco
AU - Del Giudice, Ilaria
AU - Palumbo, Giuseppe
AU - Nanni, Mauro
AU - Rinaldi, Andrea
AU - Kwee, Ivo
AU - Tissino, Erika
AU - Corradini, Giorgia
AU - Gozzetti, Alessandro
AU - Cencini, Emanuele
AU - Ladetto, Marco
AU - Coletta, Angela Maria
AU - Luciano, Fabrizio
AU - Bulian, Pietro
AU - Pozzato, Gabriele
AU - Laurenti, Luca
AU - Forconi, Francesco
AU - Di Raimondo, Francesco
AU - Marasca, Roberto
AU - Del Poeta, Giovanni
AU - Gaidano, Gianluca
AU - Foà, Robin
AU - Guarini, Anna
AU - Gattei, Valter
PY - 2011/8
Y1 - 2011/8
N2 - Deletion at 13q14 is detected by fluorescence in situ hybridization (FISH) in about 50% of chronic lymphocytic leukemia (CLL). Although CLL with 13q deletion as the sole cytogenetic abnormality (del13q-only) usually have good prognosis, more aggressive clinical courses are documented for del13q-only CLL carrying higher percentages of 13q deleted nuclei. Moreover, deletion at 13q of different sizes have been described, whose prognostic significance is still unknown. In a multi-institutional cohort of 342 del13q-only cases and in a consecutive unselected cohort of 265 CLL, we investigated the prognostic significance of 13q deletion, using the 13q FISH probes locus-specific identifier (LSI)-D13S319 and LSI-RB1 that detect the DLEU2/MIR15A/MIR16-1 and RB1 loci, respectively. Results indicated that both percentage of deleted nuclei and presence of larger deletions involving the RB1 locus cooperated to refine the prognosis of del13q-only cases. In particular, CLL carrying <70% of 13q deleted nuclei with deletions not comprising the RB1 locus were characterized by particularly long time-to-treatment. Conversely, CLL with 13q deletion in <70% of nuclei but involving the RB1 locus, or CLL carrying 13q deletion in ≥70% of nuclei, with or without RB1 deletions, collectively experienced shorter time-to-treatment. A revised flowchart for the prognostic FISH assessment of del13q-only CLL, implying the usage of both 13q probes, is proposed.
AB - Deletion at 13q14 is detected by fluorescence in situ hybridization (FISH) in about 50% of chronic lymphocytic leukemia (CLL). Although CLL with 13q deletion as the sole cytogenetic abnormality (del13q-only) usually have good prognosis, more aggressive clinical courses are documented for del13q-only CLL carrying higher percentages of 13q deleted nuclei. Moreover, deletion at 13q of different sizes have been described, whose prognostic significance is still unknown. In a multi-institutional cohort of 342 del13q-only cases and in a consecutive unselected cohort of 265 CLL, we investigated the prognostic significance of 13q deletion, using the 13q FISH probes locus-specific identifier (LSI)-D13S319 and LSI-RB1 that detect the DLEU2/MIR15A/MIR16-1 and RB1 loci, respectively. Results indicated that both percentage of deleted nuclei and presence of larger deletions involving the RB1 locus cooperated to refine the prognosis of del13q-only cases. In particular, CLL carrying <70% of 13q deleted nuclei with deletions not comprising the RB1 locus were characterized by particularly long time-to-treatment. Conversely, CLL with 13q deletion in <70% of nuclei but involving the RB1 locus, or CLL carrying 13q deletion in ≥70% of nuclei, with or without RB1 deletions, collectively experienced shorter time-to-treatment. A revised flowchart for the prognostic FISH assessment of del13q-only CLL, implying the usage of both 13q probes, is proposed.
UR - http://www.scopus.com/inward/record.url?scp=79958038921&partnerID=8YFLogxK
U2 - 10.1002/gcc.20885
DO - 10.1002/gcc.20885
M3 - Article
SN - 1045-2257
VL - 50
SP - 633
EP - 643
JO - Genes Chromosomes and Cancer
JF - Genes Chromosomes and Cancer
IS - 8
ER -
